Encompass Health Corp. executive vice president and chief operating officer Patrick William Tuer sold 2,804 shares of Encompass Health common stock in an open market transaction on February 10, 2026. The shares were sold at a weighted average price of $107.62 per share, in multiple trades ranging from $107.55 to $107.73. Following this sale, Tuer directly beneficially owns 16,042 shares of Encompass Health common stock.
Encompass Health Corporation has a shareholder filing a notice to sell 2,804 shares of its common stock under Rule 144. The planned sale through UBS Financial Services Inc. is listed with an aggregate market value of 301755, with trading on the NYSE around 02/10/2026.
The shares to be sold were acquired from Encompass Health Corporation through restricted stock unit vesting on 02/23/2024 and 02/24/2024, and performance stock unit vesting on 01/01/2025. Shares outstanding were 100,615,977 common shares at the time referenced.
Encompass Health Corporation filed a Form 8‑K to furnish its financial results for the three months and year ended December 31, 2025, as disclosed in a press release (Exhibit 99.1) and supplemental earnings materials (Exhibit 99.2).
The company explains its use of same‑store comparisons, which include hospitals open in both periods and incorporate market consolidations and capacity expansions where isolating incremental impact is difficult. It also highlights several non‑GAAP measures: adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
Encompass Health describes how Adjusted EBITDA and its leverage ratio are central to covenants in its credit agreement, affecting the ability to incur debt, pay dividends, and make certain investments. The filing also outlines the company’s definition of adjusted free cash flow and includes extensive cautionary language about forward‑looking statements tied to its strategy, growth targets, capital plans, and financial outlook.
Encompass Health Corporation reported that its Board of Directors elected Cain A. Hayes as a director on January 30, 2026, following a recommendation from its Nominating/Corporate Governance Committee. The Board has determined that Mr. Hayes is independent under New York Stock Exchange listing standards and the company’s Corporate Governance Guidelines.
Mr. Hayes will receive compensation consistent with the company’s standard practices for nonemployee directors, as described in its April 1, 2025 proxy statement. The company stated there are no arrangements or understandings with other persons related to his selection and no related party transactions involving him that require disclosure. A press release dated February 2, 2026, announcing his election, is included as an exhibit.
Encompass Health Corp reported an equity award to director Cain A. Hayes. On January 30, 2026, Hayes received 457 shares of Encompass Health common stock at a price of $0 per share, granted as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan. Following this award, Hayes directly beneficially owns 457 shares of Encompass Health common stock.
Encompass Health Corp filed an initial ownership report for director Cain A. Hayes. The filing states that, as of the event date of 01/30/2026, he is a director of the company and that no Encompass Health securities are beneficially owned.
Encompass Health Corp director Greg D. Carmichael reported receiving 28 shares of Encompass Health common stock on January 15, 2026, recorded at a price of $0 per share as a stock-based award. Following this transaction, he beneficially owned 18,659 shares directly.
The filing explains that this award reflects additional restricted stock units credited to non-employee directors in connection with common stock dividend payments. On January 15, 2026, Encompass Health paid a $0.19 per share dividend when the stock’s closing price was $102.80, and the 28 RSUs reported are tied to that dividend-related accrual.
Encompass Health Corp director Joan E. Herman reported an automatic equity award tied to the company’s common stock dividend. On January 15, 2026, she received 87 additional shares of Encompass Health common stock at a price of $0 per share, reflecting dividend-equivalent credits under outstanding restricted stock unit award agreements.
The filing notes Encompass Health paid a $0.19 per share dividend on its common stock on that date, when the stock’s closing price was $102.80. Following this award, Herman beneficially owned 47,839 shares of Encompass Health common stock directly.
Encompass Health Corp director reports dividend-linked RSU award
Encompass Health Corp director Leslye G. Katz filed a Form 4 reporting an automatic award of 87 restricted stock units (RSUs) of Encompass Health common stock on January 15, 2026. The RSUs were credited at a price of $0 per unit, increasing her directly held beneficial ownership to 47,839 shares.
According to the footnote, non-employee directors receive additional RSUs in connection with common stock dividend payments. On January 15, 2026, Encompass Health paid a cash dividend of $0.19 per share, and the RSU credit was calculated using the closing stock price of $102.80 on the dividend payment date.
Encompass Health Corp director Kevin J. O'Connor reported a small dividend-related equity grant. On January 15, 2026, he acquired 17 shares of Encompass Health common stock at a reported price of $0, bringing his directly held stake to 9,912 shares. According to the award terms, this reflects restricted stock units credited to non-employee directors in connection with common stock dividend payments. For this dividend, Encompass Health paid $0.19 per share, and the closing stock price on the payment date was $102.80, which was used to calculate the number of RSUs credited.